Modulation of chemotherapy resistance in regional therapy

A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic 06-benzylguanine

Tomio Ueno, Sae Hee Ko, Elizabeth Grubbs, Yasunori Yoshimoto, Christi Augustine, Zeinab Abdel-Wahab, Tsung Yen Cheng, Omar I. Abdel-Wahab, Scott K. Pruitt, Henry S. Friedman, Douglas Tyler

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT). Using a nude rat s.c. human melanoma xenograft model of the extremity, tumors were analyzed for AGT level 2 to 3 hours after the i.p. injection of 3.5 to 70.0 mg/kg O6BG to inhibit AGT activity. Survival studies were conducted using animals that were treated with a 15-minute isolated limb infusion with 10% DMSO in PBS (control), temozolomide alone, or temozolomide in conjunction with single or multiple doses of i.p. O6BG. Tumor volume and toxicity level were monitored every other day. Administration of 3.5 mg/kg O6BG depleted tumor AGT activity by 93.5% (P < 0.01). Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O6BG, or vehicle combined with O6BG showed no significant tumor responses compared with controls. Whereas use of regional temozolomide alone at a higher dose (750 mg/kg) showed some degree of tumor response, regional temozolomide given in conjunction with multiple dosages of O6BG showed a marked (P < 0.01) reduction in tumor growth with minimal toxicity. Our findings suggest that AGT modulation by the administration of O6BG in combination with temozolomide regional chemotherapy leads to a significant improvement in melanoma antitumor responses. Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials.

Original languageEnglish (US)
Pages (from-to)732-738
Number of pages7
JournalMolecular Cancer Therapeutics
Volume5
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

temozolomide
Melanoma
Extremities
Drug Therapy
Therapeutics
Neoplasms
Nude Rats
DNA Repair Enzymes
O(6)-benzylguanine
Dimethyl Sulfoxide
Tumor Burden
Heterografts

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Modulation of chemotherapy resistance in regional therapy : A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic 06-benzylguanine. / Ueno, Tomio; Ko, Sae Hee; Grubbs, Elizabeth; Yoshimoto, Yasunori; Augustine, Christi; Abdel-Wahab, Zeinab; Cheng, Tsung Yen; Abdel-Wahab, Omar I.; Pruitt, Scott K.; Friedman, Henry S.; Tyler, Douglas.

In: Molecular Cancer Therapeutics, Vol. 5, No. 3, 03.2006, p. 732-738.

Research output: Contribution to journalArticle

Ueno, Tomio ; Ko, Sae Hee ; Grubbs, Elizabeth ; Yoshimoto, Yasunori ; Augustine, Christi ; Abdel-Wahab, Zeinab ; Cheng, Tsung Yen ; Abdel-Wahab, Omar I. ; Pruitt, Scott K. ; Friedman, Henry S. ; Tyler, Douglas. / Modulation of chemotherapy resistance in regional therapy : A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic 06-benzylguanine. In: Molecular Cancer Therapeutics. 2006 ; Vol. 5, No. 3. pp. 732-738.
@article{bededb51d1b84fb6b15897f50bf485f7,
title = "Modulation of chemotherapy resistance in regional therapy: A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic 06-benzylguanine",
abstract = "This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT). Using a nude rat s.c. human melanoma xenograft model of the extremity, tumors were analyzed for AGT level 2 to 3 hours after the i.p. injection of 3.5 to 70.0 mg/kg O6BG to inhibit AGT activity. Survival studies were conducted using animals that were treated with a 15-minute isolated limb infusion with 10{\%} DMSO in PBS (control), temozolomide alone, or temozolomide in conjunction with single or multiple doses of i.p. O6BG. Tumor volume and toxicity level were monitored every other day. Administration of 3.5 mg/kg O6BG depleted tumor AGT activity by 93.5{\%} (P < 0.01). Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O6BG, or vehicle combined with O6BG showed no significant tumor responses compared with controls. Whereas use of regional temozolomide alone at a higher dose (750 mg/kg) showed some degree of tumor response, regional temozolomide given in conjunction with multiple dosages of O6BG showed a marked (P < 0.01) reduction in tumor growth with minimal toxicity. Our findings suggest that AGT modulation by the administration of O6BG in combination with temozolomide regional chemotherapy leads to a significant improvement in melanoma antitumor responses. Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials.",
author = "Tomio Ueno and Ko, {Sae Hee} and Elizabeth Grubbs and Yasunori Yoshimoto and Christi Augustine and Zeinab Abdel-Wahab and Cheng, {Tsung Yen} and Abdel-Wahab, {Omar I.} and Pruitt, {Scott K.} and Friedman, {Henry S.} and Douglas Tyler",
year = "2006",
month = "3",
doi = "10.1158/1535-7163.MCT-05-0098",
language = "English (US)",
volume = "5",
pages = "732--738",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Modulation of chemotherapy resistance in regional therapy

T2 - A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic 06-benzylguanine

AU - Ueno, Tomio

AU - Ko, Sae Hee

AU - Grubbs, Elizabeth

AU - Yoshimoto, Yasunori

AU - Augustine, Christi

AU - Abdel-Wahab, Zeinab

AU - Cheng, Tsung Yen

AU - Abdel-Wahab, Omar I.

AU - Pruitt, Scott K.

AU - Friedman, Henry S.

AU - Tyler, Douglas

PY - 2006/3

Y1 - 2006/3

N2 - This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT). Using a nude rat s.c. human melanoma xenograft model of the extremity, tumors were analyzed for AGT level 2 to 3 hours after the i.p. injection of 3.5 to 70.0 mg/kg O6BG to inhibit AGT activity. Survival studies were conducted using animals that were treated with a 15-minute isolated limb infusion with 10% DMSO in PBS (control), temozolomide alone, or temozolomide in conjunction with single or multiple doses of i.p. O6BG. Tumor volume and toxicity level were monitored every other day. Administration of 3.5 mg/kg O6BG depleted tumor AGT activity by 93.5% (P < 0.01). Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O6BG, or vehicle combined with O6BG showed no significant tumor responses compared with controls. Whereas use of regional temozolomide alone at a higher dose (750 mg/kg) showed some degree of tumor response, regional temozolomide given in conjunction with multiple dosages of O6BG showed a marked (P < 0.01) reduction in tumor growth with minimal toxicity. Our findings suggest that AGT modulation by the administration of O6BG in combination with temozolomide regional chemotherapy leads to a significant improvement in melanoma antitumor responses. Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials.

AB - This study investigated whether the therapeutic index of regional melanoma therapy using parenteral temozolomide could be improved by chemomodulation with O6-benzylguanine (O6BG), an inhibitor of the DNA repair enzyme O6-alkylguanine-DNA alkyltransferase (AGT). Using a nude rat s.c. human melanoma xenograft model of the extremity, tumors were analyzed for AGT level 2 to 3 hours after the i.p. injection of 3.5 to 70.0 mg/kg O6BG to inhibit AGT activity. Survival studies were conducted using animals that were treated with a 15-minute isolated limb infusion with 10% DMSO in PBS (control), temozolomide alone, or temozolomide in conjunction with single or multiple doses of i.p. O6BG. Tumor volume and toxicity level were monitored every other day. Administration of 3.5 mg/kg O6BG depleted tumor AGT activity by 93.5% (P < 0.01). Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O6BG, or vehicle combined with O6BG showed no significant tumor responses compared with controls. Whereas use of regional temozolomide alone at a higher dose (750 mg/kg) showed some degree of tumor response, regional temozolomide given in conjunction with multiple dosages of O6BG showed a marked (P < 0.01) reduction in tumor growth with minimal toxicity. Our findings suggest that AGT modulation by the administration of O6BG in combination with temozolomide regional chemotherapy leads to a significant improvement in melanoma antitumor responses. Clinical trials using chemotherapy modulation may improve response rates in future regional infusion and perfusion drug trials.

UR - http://www.scopus.com/inward/record.url?scp=33645474059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645474059&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-05-0098

DO - 10.1158/1535-7163.MCT-05-0098

M3 - Article

VL - 5

SP - 732

EP - 738

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -